S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
NASDAQ:NDRA

ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

$1.15
0.00 (0.00%)
(As of 02/23/2024 06:55 PM ET)
Today's Range
$1.10
$1.27
50-Day Range
$1.00
$2.50
52-Week Range
$0.87
$4.02
Volume
151,700 shs
Average Volume
100,516 shs
Market Capitalization
$12.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

ENDRA Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
682.6% Upside
$9.00 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of ENDRA Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

404th out of 935 stocks

Electromedical Equipment Industry

6th out of 21 stocks


NDRA stock logo

About ENDRA Life Sciences Stock (NASDAQ:NDRA)

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NDRA Stock Price History

NDRA Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
ENDRA Life Sciences Inc (NDRA)
ENDRA Life Sciences Inc.
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
ENDRA Life Sciences: Q3 Earnings Insights
Earnings Preview: ENDRA Life Sciences
See More Headlines
Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/26/2024
Next Earnings (Estimated)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:NDRA
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+682.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.28 per share

Miscellaneous

Free Float
10,506,000
Market Cap
$12.70 million
Optionable
Not Optionable
Beta
1.00
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Francois Michelon (Age 58)
    Chairman, President & CEO
    Comp: $423.59k
  • Mr. Michael Thornton Ph.D. (Age 56)
    Chief Technology Officer
    Comp: $301.67k
  • Dr. Jonathan Behr Ph.D.
    Co-Founder
  • Ms. Irina Pestrikova (Age 37)
    Senior Director of Finance & Secretary
  • Mr. Steve Freeman
    Human Resources Leader














NDRA Stock Analysis - Frequently Asked Questions

Should I buy or sell ENDRA Life Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NDRA shares.
View NDRA analyst ratings
or view top-rated stocks.

What is ENDRA Life Sciences' stock price target for 2024?

1 brokers have issued twelve-month price objectives for ENDRA Life Sciences' stock. Their NDRA share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 682.6% from the stock's current price.
View analysts price targets for NDRA
or view top-rated stocks among Wall Street analysts.

How have NDRA shares performed in 2024?

ENDRA Life Sciences' stock was trading at $2.12 at the beginning of 2024. Since then, NDRA stock has decreased by 45.8% and is now trading at $1.15.
View the best growth stocks for 2024 here
.

Are investors shorting ENDRA Life Sciences?

ENDRA Life Sciences saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 19,900 shares, a decrease of 73.7% from the January 15th total of 75,700 shares. Based on an average daily volume of 99,800 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the shares of the stock are sold short.
View ENDRA Life Sciences' Short Interest
.

When is ENDRA Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our NDRA earnings forecast
.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. During the same period in the prior year, the company posted ($0.15) earnings per share.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), electroCore (ECOR) and Genocea Biosciences (GNCA).

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NDRA) was last updated on 2/26/2024 by MarketBeat.com Staff